Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

Europe’s leading cancer conference may be swimming in antibody-drug conjugate (ADC) data, but AstraZeneca remains convinced ...

The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...

To unpack what the new policy means for drug developers, Fierce Biotech’s Darren Incorvaia sat down with Torrey Cope, a ...

The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and ...

Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...

Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash ...

A pair of antibody-based biotech deals emerged late this week, encompassing separate licensing pacts from China’s Hansoh ...

A year ago, Pfizer tied a subcutaneous injection of the highest dose of the anti-GDF-15 antibody ponsegromab once every four ...

Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. | The ...

President Donald Trump has telegraphed a new round of 100% tariffs on all Chinese imports beginning in November. The U.S. has ...

The latest strand in Pelage Pharmaceuticals’ growing funds comes from a $120 million series B fundraising round that the ...